上海君派英实药业

Junpai Yingshi Pharmaceutical is a joint venture established by Shanghai Junshi Biosciences and Impact Therapeutics to focus on the development and commercialization of oncology treatments. The company's primary asset is Senaparib (IMP4297), a highly potent and selective small molecule PARP inhibitor designed for the treatment of various solid tumors. Senaparib has demonstrated a favorable safety profile and significant efficacy in clinical trials, particularly as a maintenance therapy for patients with advanced ovarian cancer. By combining the research expertise of Impact Therapeutics in DNA damage response with Junshi Biosciences' robust clinical and commercial infrastructure, Junpai Yingshi aims to accelerate the delivery of innovative therapies to the Chinese market. The company is currently advancing Senaparib through the regulatory approval process and exploring its potential in combination therapies.